However, p14/Arf mutations are associated with other cancer types, and the two protein products act in connected pathways—p53 signaling promotes, as necessary, cell cycle arrest, apoptosis, or senescence and is also a negative regulator of p14/Arf expression [22],[23]. The gene discussed is CDKN2A; the disease is cancer.